Skip to main
DRTS

DRTS Stock Forecast & Price Target

DRTS Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 60%
Buy 20%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Tau Medical is a clinical-stage oncology therapeutics company with a positive outlook due to its innovative Alpha DaRT technology, which has shown promising results in treating various types of solid tumors in clinical trials. Their recent partnerships, such as the one with Tolmar for developing and commercializing Alpha DaRT for prostate cancer in the US, demonstrate the potential for increased revenue and market expansion. Furthermore, the company has a strong financial position with a projected market value of $1.31 billion and promising clinical data, making it a favorable investment opportunity for long-term growth. However, risks to consider include potential failures in clinical trials and regulatory approvals, as well as competition in the market.

Bears say

Alpha Tau Medical is a clinical-stage oncology therapeutics company with a negative outlook due to its limited market size and potential competition, as well as potential risks related to the failure of Alpha DaRT in clinical trials and achieving commercial success. The company's valuation is derived from a DCF analysis-based asset value of $1.23B, with a discounted cash flow analysis that includes a 15% discount rate and 2% terminal growth rate. Risks also include potential dilution risk and failure to secure regulatory approval in the US.

DRTS has been analyzed by 5 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 20% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Tau Medical (DRTS) Forecast

Analysts have given DRTS a Buy based on their latest research and market trends.

According to 5 analysts, DRTS has a Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Tau Medical (DRTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.